Insmed (Nasdaq: INSM) provided a status update on their development program. After recently receiving approval form the UK Medicines and Healthcare Regulatory Agency to initiate a clinical trial for INS-19 [a follow-on biologic of Amgen’s (Nasdaq: AMGN) Neupogen®] patient screening has begun and the first dosing is expected next month with similarity data to be [...]

• 384http://clsdf.com/2008/04/insmed-meeting-milestones/Insmed%3A+Meeting+Milestones%212008-04-30+13%3A58%3A00admin

Two MBA students at the University of Colorado, Bard Center for Entrepreneurship are examining how their institution may better support the Colorado life science ecosystem via the delivery of specifically tailored graduate degrees, certificates and continuing education offerings that may ultimately empower, improve and expand the local workforce. Kindly set aside five minutes of your [...]

• 383http://clsdf.com/2008/04/bard-center-needs-your-help/Bard+Center+Needs+Your+Help%212008-04-30+13%3A53%3A00admin